samedan logo
 
 
spacer
home > ebr > winter 2003 > colours as registered trademarks
PUBLICATIONS
European BioPharmaceutical Review

Colours as Registered Trademarks

The pharmaceutical industry has been moving away from the traditional research-driven business model to one which is motivated by the marketing of major branded products. Compelled by the need to create bestseller products and then defend their sales post-patent expiry, pharmaceutical companies are increasingly using the power of branding to capture the hearts and minds of the public.

Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sara Elwyn Jones, Associate at Taylor Wessing

Sara Elwyn Jones is an Associate in the intellectual property department of the London office of Taylor Wessing, an international law firm. After studying Law and French at Cardiff University and taking her Law Society finals at Nottingham, Sara trained for two years with the firm before qualifying into the intellectual property department two years ago. Sara specialises in all aspects of intellectual property including both contentious and non-contentious work.

spacer
Sara Elwyn Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Biovian expands - and invests in new capacity

 
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement